Medios AG (ILM1) AI Stock Analysis

0 Followers

Medios AG

(BX Swiss:ILM1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Broad revenue growthBroad-based revenue growth across all business segments indicates expanding demand rather than reliance on one activity. Continued momentum in specialty therapies and pharmaceutical supply can support scale benefits, strengthen customer relationships, and provide a durable platform for further organic and inorganic growth.

Negative Factors

Thin profitabilityVery thin profitability leaves Medios highly sensitive to pricing, product mix, operating costs, and other changes below the revenue line. The decline in net income despite strong sales growth indicates that expansion is not yet translating proportionately into shareholder earnings, limiting financial resilience.

Medios AG (ILM1) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 1.28B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 25.8
Beta (1Y): 1.49
Revenue Growth: 6.88%
EPS Growth: -62.47%
Country: Switzerland
Employees: 989
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Distribution

Medios AG Business Overview & Revenue Model

Company Description

Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies...

Medios AG Earnings Call Summary

Earnings Call Date:Nov 10, 2026(Q3-2026)|% Change Since:-0.97%|Next Earnings Date:Jun 02, 2020

Earnings Call SentimentPositive

The call had a positive overall tone. Revenue growth was broad-based, patient-specific therapies showed clear margin improvement, operational-efficiency measures were producing savings, financing was strengthened, and full-year guidance was confirmed. These positives outweighed ongoing pricing pressure, lower margins and earnings, weaker operating cash flow, elevated taxes, and regulatory uncertainty.

Positive Updates

Broad-Based Revenue Growth

Revenue for the first 9 months reached EUR 1.633 billion, an increase of 6.7% year over year, with all business segments contributing to growth. Q3 revenue was EUR 558 million.

Negative Updates

Gross Profit and EBITDA Margin Pressure

The EBITDA pre margin declined to 4.1% from 4.6% in the prior year. Management attributed the reduction primarily to pricing pressure in pharmaceutical supply and temporarily higher material costs in the international business.

Company Guidance

Medios confirmed guidance for 2026 in terms of EBITDA and sales for the fourth quarter and full year 2026, while expecting to be on the lower side of the EBITDA corridor and implying a little more than EUR 21 million for Q4 EBITDA pre; the guidance excludes Caelo and did not include the approx EUR 1.2 million Hilfstaxe impact, with Avanti Medios! expected to deliver EUR 5 million for 2026, of which 2.7 are already now -- or 2.5 are already now realized. Operating cash flow is expected to be around EUR 40 million, while EUR 50 million plus/minus is the normal cash flow expected in a normal year and EUR 40 million, EUR 45 million reflects eliminating this year’s impacts; this is not a guidance. CapEx is expected to remain around EUR 10 million in a year, the tax rate next year is expected to be below 40%, with something between 35% to 40% max, and Medios reiterated its ambition to increase the business from EUR 2.1 billion to EUR 3.1 billion until 2031, with about EUR 325 million planned for M&A.

Medios AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:ILM1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:M12	79Outperform	EUR 341.95M	17.87	16.58%	6.16%	-27.50%	13.64%
DE:LIK	67Neutral	EUR 162.00M	31.11	22.18%	1.74%	35.46%	17.88%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DE:MAK	45Neutral	EUR 17.51M	-1.26	16.80%	―	2.73%	-1.80%

* Healthcare Sector Average

Performance Comparison

CH:ILM1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:ILM1	Medios AG	10.46	-1.25	-10.64%
DE:MAK	MATERNUS-Kliniken AG	0.82	-0.29	-26.13%
DE:LIK	Limes Schlosskliniken AG	575.00	235.59	69.41%
DE:EIF	Eifelhoehen-Klinik AG	3.90	0.84	27.45%
DE:JTH0	Gesundheitswelt Chiemgau AG	12.00	0.00	0.00%
DE:M12	M1 Kliniken AG	19.48	6.02	44.70%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Medios AG AI Stock Analysis